Novavax agrees huge supply deal with Gavi for 1.1 billion doses of COVID-19 vaccine
Biotech will manufacture shots with partner SII for equitable vaccine distribution programme, COVAX
Novavax has struck a huge deal with international vaccine alliance, Gavi, to supply 1.1 billion doses of NVX-CoV2373, the biotech’s recombinant protein-based COVID-19 vaccine candidate, for COVAX, the equitable global vaccine distribution programme.
The vaccine doses will be manufactured and distributed by Novavax and Serum Institute of India (SII), the latter under an existing agreement between Gavi and SII.
The vaccine is currently in Phase III clinical trials in the US, Mexico, and the UK for the prevention of COVID-19. Novavax has previously reported positive interim efficacy results from the UK trial.
Gavi is working alongside the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO) on COVAX, which is the vaccines arm of the Access to COVID-19 Tools Accelarator and currently includes more than 190 participating countries.
Gavi leads the design and implementation of COVAX and will work with Novavax to finalize an advance purchase agreement for vaccine supply and global distribution allocation via the programme.
CEPI has committed approximately $400 million to advance early clinical development and manufacturing scale-up of the Novavax vaccine in several facilities around the world. Novavax licensed its NVX-CoV2373 technology to SII with no upfront, milestone or technology transfer payments.
For supply of NVX-CoV2373 to COVAX, Novavax is expected to supply doses primarily to high-income countries, with SII providing the majority of supply for low-, middle, and upper-middle-income countries, using a tiered pricing schedule.
Dr. Seth Berkley, CEO of Gavi, said the agreement brought COVAX a step closer to its goal of supplying vaccines globally and ending the acute phase of the pandemic: “It helps us close in on our goal of delivering two billion doses in 2021 and increases the range of vaccines available to us as we build a portfolio suitable for all settings and contexts.”
NVX-CoV2373 was the first vaccine to demonstrate clinical efficacy against the original strain of COVID-19 and both of the rapidly emerging variants in the UK and South Africa and is shipped in a ready-to-use liquid formulation. Because it is stable when refrigerated, existing vaccine supply chain channels can be used for its distribution.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance